The present invention relates to novel 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

Disclosed herein include engineered opioid biosensors, and related compositions, vectors, cells, and systems. Also disclosed include methods that provide opioid biosensors with sensitivity and selectivity suitable for continuous opioid monitoring as well as the use of the opioid biosensors for detecting one or more specific opioids. The opioid biosensors, which are capable of undergoing a detectable conformational change upon binding to an opioid, can each comprise a first periplasmic binding protein (PBP) domain and a second PBP domain connected to the first PBP domain, wherein at least one of the first PBP domain and the second PBP domain comprises one or more mutations.

The present invention relates to roadside analyzer for determination of illegal drugs abuse, including, but not limiting to detection of explosives, toxic industrial chemicals and other banned or regulated compounds, biomarkers and phytochemicals in a sample in situ in at least one human body fluid sample, specifically in oral fluid (saliva), but not limiting to other clinical samples of interest (urine, blood, exhaled breath, exhaled breath condensate, etc.) It consists of automatic processor for preparing samples suitable for analysis. Analysis part of the instrument implements three technologies, namely solid phase extraction prior to analysis, capillary electrophoresis for separation of analytes from the sample matrix and impedance (contactless conductivity) or fluorescence or both impedance (contactless conductivity) and fluorescence for detection of analytes of interest.

It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.

The present invention relates to a method for determining the presence or level of an analyte of interest and the use thereof. Further, present invention relates to an analytical system, a sampling tube and the use of the sampling tube and a nucleophilic derivatization reagent.

The present invention provides an apparatus for detecting the presence or absence of an analyte in liquid sample, including: a collection chamber, including an opening for collecting a liquid sample; a testing element for testing the analyte in liquid sample; and a cover for covering the opening of the collection chamber; wherein the apparatus further includes a prompting device for prompting if the cover is covered to a specified location, and the prompting device shall at least includes a first element and a second element, the first element is in contact with the second element, wherein one element vibrates to produce a sound. In some preferred ways, the second element produces friction with the first element, to cause one of the elements to generate vibrations. The apparatus in the present invention can allow the prompting sound to be clear and loud.

Embodiments of the invention provides methods and devices which enable a quick, easy, and cost-effective test for detecting the presence of coagulation factor (CF) inhibitors and platelet (P) inhibitors within small volumes of patient-derived liquid samples. The inventive approach reduces the need for elaborate and time-consuming sample testing or larger quantities of a sample to be collected. The inventive approach overcomes further limitations by providing a detection method that is suitable for measuring antiplatelet drugs, as well as methods for detecting CF inhibitors which are not dependent on competition between CF inhibitors and chromogenic substrates and enzymatic cleaving, but instead relies on non-competitive configurations involving the use of sequential binding moieties with specificity toward CF/P inhibitors and subsequent complexes and/or competitive configurations involving the use of binding moieties that will compete for CF inhibitors against either modified CF inhibitors or other competing moieties.

This disclosure relates to methods and kits for determining the presence and/or amount of one or more analytes in a keratinized structure (e.g., hair) sample.

The present invention discloses a detection apparatus, comprising a base layer, wherein the base layer comprises a groove for containing a testing element and a sample chamber for collecting a fluid sample. The detection apparatus can achieve fast, efficient and accurate detection of analytes in liquid samples, make operators to perform testing conveniently and freely, without causing incorrect results. In some preferred modes, the sample chamber comprises a liquid channel.

The subject invention provides materials and methods for single-step detection of target molecules in a sample. The methods and assays of the subject invention employ a dye-displacement strategy, in which aptamers complexed with a cyanine dye for sensitive and rapid detection of targets of interest. In the presence of a target, aptamer-target binding liberates the non-covalently bound aptamer-binding dye, resulting in optical changes that can be observed spectrophotometrically or with the naked eye. The methods and assays of the subject invention enable the colorimetric detection of targets of interest regardless of their structure, sequence, target-binding affinity, and physicochemical properties of their targets.